In clinical R&D enrollment feasibility studies, I typically see all manner of questions aimed toward potential investigators that seek to establish (with accuracy) the number of patients they see, treat, and manage on a daily / weekly / monthly / quarterly basis. Typically, the question is confounded with layers of study eligibility criteria, and so the answer of course is rarely given with anything close to accuracy.
Although my high school glory days are over, I still compete in two men’s basketball leagues. The way each team functions is vastly different for one big reason: process. Let’s take a look at each scenario and how that affects each team’s success.
The ascent of the buzzword “innovation” in our industry conferences, articles, and blogs has been meteoric. Not sure about you, but for me it has become so mainstream and overused at this point that the word is now a popular cliché – something that is, in and of itself, indolent and predictable.
For this blog Matt Kibby, our BBK Principal who oversees the TCN team, worked with Rakesh Chittineni to describe a new feature of the system called StudyGram.
Editor’s note: This blog is the fifth in a seven-part series on TrialCentralNetSM (TCN), a single infrastructure for managing everything from enrollment metrics to clinical trial reference documents through all phases of development and approval, as well as customized reports, training, and communications. The goal of this series is to give you the “backstory” – a BBK insider’s view of the system from the perspectives of those who build, manage, and rely on it. In their own words, our executive leadership, developers, and power users all tell it like it is. They’re passionate about the system they so tirelessly build and manage – and you’ll hear that come through in their writing.
This blog is from Matt Kibby, our BBK Principal who oversees the TCN team. In this blog, Matt talks about document management.
It’s a common practice in our industry (at least from my vantage point) to hear talk of the screen failure “rate” of any given study.
If there was ever a clinical R&D version of the TV show, Jeopardy! I think that one of the categories might go something like this:
Around nine years ago when BBK began expanding into the global clinical trial arena, fashioning recruitment strategies and materials that could be used to better effectively communicate clinical trial opportunities to patients, we found that many sponsors, CROs and other partner organizations were very skeptical about whether audiences outside the United States would approve.
In the world of clinical R&D technology solutions, we commonly are asked to be able to provide our groundbreaking information TrialCentralNet® portal in multiple languages.